Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis

Intensive Care Medicine

Volumn 41, Issue 8, 2015, Pages 1393-1401

  Shankar Hari, Manu ^a,b   Culshaw, Nicholas ^a   Post, Benjamin ^a   Tamayo, Eduardo ^c   Andaluz Ojeda, David ^c   Bermejo Martín, Jesús F ^c   Dietz, Sebastian ^d   Werdan, Karl ^d   Beale, Richard ^a,b   Spencer, Jo ^b   Singer, Mervyn ^e  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d St Marien Krankenhaus Siegen gem GmbH   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adult; Immunoglobulin; Mortality; Sepsis; Survival rate

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INTENSIVE CARE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; SURVIVOR; SYSTEMATIC REVIEW; ADULT; AGAMMAGLOBULINEMIA; AGED; BLOOD; CRITICAL ILLNESS; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

ADULT; AGAMMAGLOBULINEMIA; AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RISK FACTORS; SEPSIS; SURVIVAL RATE;

EID: 84937814786     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-3845-7     Document Type: Review

References (35)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, Sccm/Esicm/Accp/Ats/Sis (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256
2. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851
3. Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A (2014) The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 20:224–233
4. Marshall JC (2014) Why have clinical trials in sepsis failed? Trends Mol Med 20:195–203
5. Shankar-Hari M, Deutschman CS, Singer M (2015) Do we need a new definition of sepsis? Intensive Care Med. doi:10.1007/s00134-015-3680-x
6. Soares MO, Welton NJ, Harrison DA, Peura P, Shankar-Hari M, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM (2012) An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess 16:1–186
7. Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M (2012) Bench-to-bedside review: immunoglobulin therapy for sepsis—biological plausibility from a critical care perspective. Crit Care 16:206
8. Biomarkers Definitions Working G (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
9. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A (2010) Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol 7:309–317
10. (2014) Abstracts for ESICM-Barcelona 2014. Intensive Care Med 40(Suppl 1):1–308
11. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
12. Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:1481–1483
13. Andaluz-Ojeda D, Iglesias V, Bobillo F, Almansa R, Rico L, Gandia F, Loma AM, Nieto C, Diego R, Ramos E, Nocito M, Resino S, Eiros JM, Tamayo E, de Lejarazu RO, Bermejo-Martin JF (2011) Early natural killer cell counts in blood predict mortality in severe sepsis. Crit Care 15:R243
14. Bermejo-Martin JF, Rodriguez-Fernandez A, Herran-Monge R, Andaluz-Ojeda D, Muriel-Bombin A, Merino P, Garcia-Garcia MM, Citores R, Gandia F, Almansa R, Blanco J, Group G (2014) Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med 276:404–412
15. Huang SW, Chen J, Ouyang B, Yang CH, Chen MY, Guan XD (2009) Immunotherapy improves immune homeostasis and increases survival rate of septic patients. Chin J Traumatol 12:344–349
16. Ekdahl K, Rollof J, Oxelius VA, Engellau J, Braconier JH (1994) Analysis of immunoglobulin isotype levels in acute pneumococcal bacteremia and in convalescence. Eur J Clin Microbiol Infect Dis 13:374–378
17. Heredia-Rodriguez M, Gutierrez-Junco S, Gomez-Sanchez E, Alvarez-Fuente E, Ruiz-Granado P, Almansa R (2013) Endogenous immunoglobulin subclasses and isotypes in septic shock patients in the postoperative period. Eur J Anaesthesiol 30:185
18. Venet F, Gebeile R, Bancel J, Guignant C, Poitevin-Later F, Malcus C, Lepape A, Monneret G (2011) Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol 11:2086–2090
19. Tamayo E, Fernandez A, Almansa R, Carrasco E, Goncalves L, Heredia M, Andaluz-Ojeda D, March G, Rico L, Gomez-Herreras JI, de Lejarazu RO, Bermejo-Martin JF (2012) Beneficial role of endogenous immunoglobulin subclasses and isotypes in septic shock. J Crit Care 27:616–622
20. Taccone FS, Stordeur P, De Backer D, Creteur J, Vincent JL (2009) Gamma-globulin levels in patients with community-acquired septic shock. Shock 32:379–385
21. Almansa R, Wain J, Tamayo E, Andaluz-Ojeda D, Martin-Loeches I, Ramirez P, Bermejo-Martin JF (2013) Immunological monitoring to prevent and treat sepsis. Crit Care 17:109
22. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues HH, Verner L, Neumann R, Muller-Werdan U, Score-Based Immunoglobulin Therapy of Sepsis Study G (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693–2701
23. Dietz S, Lautenschlaeger C, Mueller-Werdan U, Werdan K (2010) Low levels of immunoglobulin G in patients with sepsis or septic shock: a signum mali ominis? Crit Care 14:P26
24. Shankar-Hari M, Singer M, Cornelius V, Sanderson B, Gordon A, Terblanche M, Rowan K, Beale R, Spencer J (2013) Low immunoglobulin G levels at admission reduced the odds for 28 day mortality compared to normal levels: prospective cohort study in severe sepsis. Intensive Care Med 39(2):151 (abstract 0177)
25. Myrianthefs PM, Boutzouka E, Baltopoulos GJ (2010) Gamma-globulin levels in patients with community-acquired septic shock. Shock 33:556–557; author reply 557
26. Lee WL, Slutsky AS (2010) Sepsis and endothelial permeability. N Engl J Med 363:689–691
27. Michaelsen TE, Sandlie I, Bratlie DB, Sandin RH, Ihle O (2009) Structural difference in the complement activation site of human IgG1 and IgG3. Scand J Immunol 70:553–564
28. Nordenfelt P, Waldemarson S, Linder A, Morgelin M, Karlsson C, Malmstrom J, Bjorck L (2012) Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med 209:2367–2381
29. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS (2014) Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 42:383–391
30. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA (2005) Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 174:3765–3772
31. Inoue S, Suzuki-Utsunomiya K, Okada Y, Taira T, Iida Y, Miura N, Tsuji T, Yamagiwa T, Morita S, Chiba T, Sato T, Inokuchi S (2013) Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit Care Med 41:810–819
32. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306:2594–2605
33. Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM (2012) A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 16:R112
34. de Pablo R, Monserrat J, Prieto A, Alvarez-Mon M (2014) Role of circulating lymphocytes in patients with sepsis. BioMed Res Int 2014:671087
35. Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC (2014) The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med 42:1714–1721